指南与共识心脑血管急症重症综合管理与镇静镇痛

动脉粥样硬化血栓形成与血栓栓塞:第二届马斯特里赫特血栓形成共识会议立场文件

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
指南 / 共识 · Thromb Haemost · 2018-01-29
一句话结论共识专家提出动脉粥样硬化血栓形成在危险因素、循环细胞、凝血蛋白酶及防治方面的多项研究重点与共识建议,涉及FXI、PAR-4、血小板功能检测指导抗血小板治疗等方向。

本立场文件来自第二届马斯特里赫特血栓形成共识会议,由基础到临床的多学科科学家讨论后形成,反映专家意见与共识建议。文件围绕五个主题:危险因素、生物标志物与斑块不稳定性;循环细胞包括血小板与动脉粥样硬化血栓形成;凝血蛋白酶、纤维蛋白(原)与血栓形成;动脉粥样硬化血栓形成与动脉栓塞的预防和急性治疗;凝血蛋白酶多效性、血栓溶解与缺血再灌注。内容以研究方向和共识建议为主,涉及FXI在血栓形成中的作用、PAR-4与PAR-1作为抗血栓靶点、心房颤动风险评分改进、口服抗凝治疗的组织与急诊可及性、快速敏感实验室检测需求等。

要点

  • 共识认为需更关注特定危险因素如异位脂肪对动脉粥样硬化血栓形成的贡献,并重视区分疾病不同阶段包括斑块(不)稳定性的定义。
  • 共识指出FXI是连接血小板、凝血酶生成与炎症机制的关键调节因子,其作用呈肾素-血管紧张素依赖方式;FXI在血栓形成中与安全有效抗血栓治疗相关的下限范围有待确立。
  • 共识认为PAR-4相对于PAR-1作为抗血栓治疗靶点值得研究;正在进行的基于血小板功能检测调整抗血小板治疗的试验支持开发实际可行的检测方法。
  • 共识认为心房颤动患者风险评分需改进并纳入包括凝血指标在内的新生物标志物;考虑器官系统出血差异的风险评分可能有附加价值。
  • 共识指出所有形式的口服抗凝治疗都需要更好的组织管理,包括教育和急诊可及性;实验室检测仍需快速可用、敏感且周转时间短的检测方法。

适用人群与场景

  • 涉及动脉粥样硬化血栓形成与血栓栓塞的基础到临床研究及防治,涵盖动脉粥样硬化、心房颤动、缺血性卒中等人群场景

处置流程与药物剂量

  • 共识指出所有形式的口服抗凝治疗都需要更好的组织管理,包括教育和急诊可及性。
  • 共识指出实验室检测仍需快速可用、敏感且周转时间短的检测方法。
  • 共识指出基于血小板功能检测调整抗血小板治疗的正在进行的试验支持开发实际可行的检测方法。

研究设计与关键结果

  • 本文件为第二届马斯特里赫特血栓形成共识会议立场文件,由基础到临床的多学科科学家讨论,所有报告与听众讨论后结果纳入最终文件,呈现专家意见与共识建议的最新反映。
  • 主题一:动脉粥样硬化血栓形成研究中需更多关注特定危险因素如异位脂肪的贡献;动脉粥样硬化血栓形成的定义对区分疾病不同阶段包括斑块(不)稳定性很重要;蛋白组学和代谢组学数据应加入遗传信息。
  • 主题二:需考虑小鼠动脉粥样硬化中白细胞和巨噬细胞可塑性、迁移和转化的机制;需识别基于疾病机制的生物标志物;需纳入全血流的实验系统以理解红细胞如何影响血栓形成和稳定性;血小板异质性和致敏条件的知识需转化至体内情况。
  • 主题三:需确立FXI在血栓形成中的作用包括与该因子相关的安全有效抗血栓治疗的下限范围;FXI以肾素-血管紧张素依赖方式连接血小板、凝血酶生成和炎症机制,是关键调节因子,但对凝血酶依赖PAR信号的影响需进一步研究;需探索FXIII生物学和生物化学的基本机制及其对血栓生物物理特性的影响;需解决红细胞与纤维蛋白形成的相互作用及其对血栓形成和溶解的后果;血小板-纤维蛋白相互作用是血栓形成和稳定性的关键决定因素,具有潜在治疗意义。
  • 主题四:PAR-4相对于PAR-1作为抗血栓治疗靶点值得研究;正在进行的基于血小板功能检测调整抗血小板治疗的试验支持开发实际可行的检测方法;心房颤动患者风险评分需改进并纳入包括凝血指标在内的新生物标志物;考虑器官系统出血差异的风险评分可能有附加价值;所有形式的口服抗凝治疗都需要更好的组织管理,包括教育和急诊可及性;实验室检测仍需快速可用、敏感且周转时间短的检测方法。
  • 主题五:需要专门用于血栓储存和分析的生物样本库;需要进一步研究新型修饰活化蛋白C基制剂包括其细胞保护特性;需要优化缺血性卒中患者治疗的新途径,也包括改变纤溶活性的新型制剂(靶向纤溶酶原激活物抑制剂-1和凝血酶激活的纤溶抑制剂)。

证据类型、等级与局限

  • 证据类型:共识会议立场文件(专家意见与共识建议)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 共识提出FXI在血栓形成中的作用及其与安全有效抗血栓治疗相关的下限范围有待确立,提示该方向可能影响未来抗血栓治疗策略的研究与评估。
  • 共识提出PAR-4相对于PAR-1作为抗血栓治疗靶点值得研究。
  • 共识提出基于血小板功能检测调整抗血小板治疗的正在进行的试验支持开发实际可行的检测方法。
  • 共识提出心房颤动患者风险评分需改进并纳入包括凝血指标在内的新生物标志物,考虑器官系统出血差异的风险评分可能有附加价值。
  • 共识提出所有形式的口服抗凝治疗都需要更好的组织管理,包括教育和急诊可及性;实验室检测仍需快速可用、敏感且周转时间短的检测方法。

指南或共识出处

  • 第二届马斯特里赫特血栓形成共识会议立场文件(Thromb Haemost)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque instability: In atherothrombosis research, more focus on the contribution of specific risk factors like ectopic fat needs to be considered; definitions of atherothrombosis are important distinguishing different phases of disease, including plaque (in)stability; proteomic and metabolomics data are to be added to genetic information. 2. Circulating cells including platelets and atherothrombosis: Mechanisms of leukocyte and macrophage plasticity, migration, and transformation in murine atherosclerosis need to be considered; disease mechanism-based biomarkers need to be identified; experimental systems are needed that incorporate whole-blood flow to understand how red blood cells influence thrombus formation and stability; knowledge on platelet heterogeneity and priming conditions needs to be translated toward the in vivo situation. 3. Coagulation proteases, fibrin(ogen) and thrombus formation: The role of factor (F) XI in thrombosis including the lower margins of this factor related to safe and effective antithrombotic therapy needs to be established; FXI is a key regulator in linking platelets, thrombin generation, and inflammatory mechanisms in a renin-angiotensin dependent manner; however, the impact on thrombin-dependent PAR signaling needs further study; the fundamental mechanisms in FXIII biology and biochemistry and its impact on thrombus biophysical characteristics need to be explored; the interactions of red cells and fibrin formation and its consequences for thrombus formation and lysis need to be addressed. Platelet-fibrin interactions are pivotal determinants of clot formation and stability with potential therapeutic consequences. 4. Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways and tailoring? The role of protease-activated receptor (PAR)-4 vis à vis PAR-1 as target for antithrombotic therapy merits study; ongoing trials on platelet function test-based antiplatelet therapy adjustment support development of practically feasible tests; risk scores for patients with atrial fibrillation need refinement, taking new biomarkers including coagulation into account; risk scores that consider organ system differences in bleeding may have added value; all forms of oral anticoagulant treatment require better organization, including education and emergency access; laboratory testing still needs rapidly available sensitive tests with short turnaround time. 5. Pleiotropy of coagulation proteases, thrombus resolution and ischaemia-reperfusion: Biobanks specifically for thrombus storage and analysis are needed; further studies on novel modified activated protein C-based agents are required including its cytoprotective properties; new avenues for optimizing treatment of patients with ischaemic stroke are needed, also including novel agents that modify fibrinolytic activity (aimed at plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor.

来源:Thromb Haemost,查看原文。版权归原作者所有。

参考来源

  1. Spronk HMH, Padro T, Siland JE, et al. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thromb Haemost. 2018. PMID: 29378352. doi:10.1160/TH17-07-0492

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。